搜索 联络表
This page is available in multiple languages
Select Language

Inify Laboratories lists on Euronext Growth Oslo

Back

  • The sixth listing on Euronext Growth Oslo in 2022
  • Market capitalisation of approximately NOK 181 million

 

Oslo – 20 June 2022 – Oslo Børs, part of the Euronext Group, today congratulate Inify Laboratories AB (ticker: INIFY) on their listing on Euronext Growth Oslo. This is the sixth listing on Euronext Growth Oslo so far in 2022.  

Inify Laboratories is a Swedish company providing cancer diagnostics through ultra-modern laboratory services within pathology. It uses a fully digital, standardized and AI-supported workflow to optimize quality and response times, initially within prostate cancer. The company is currently building an ultra-modern laboratory located at Solna, Sweden. The company is a spin-off from the Oslo Børs listed MedTech company ContextVision.

At opening, the share price was set at NOK 4, corresponding to a total estimated value of NOK 181 million  

Fredrik Palm, CEO of Inify Laboratories said: “I’m truly thrilled to announce that Inify Laboratories is admitted to trading on Euronext Growth Oslo, less than 5 months after we became independent. With solid funding of NOK 150 million, provided through an equity issue towards supportive long-term shareholders as well as the management and Board of Directors, we have all prerequisites in place to develop the company and create a monumental paradigm shift within cancer diagnostics. The concept is scalable in terms of volume, diagnoses and geographical expansion which enable us to advance fast and create value for patients and clinicians. We offer a unique, attractive workplace for our multidisciplinary team where we merge technical and medical expertise in the same organization, sharing our vision to deliver world-leading cancer diagnostics.”

 

About Inify Laboratories AB

Inify Laboratories provides cancer diagnostics through ultra-modern laboratory services within histopathology. Fully digital, standardized and AI- supported workflow is applied to optimize quality and response times, initially for prostate cancer. The concept is scalable and extendible to other diagnosis. The company origins from ContextVision and became independent in February 2022. The company is based in Sweden and listed on Euronext Growth Oslo under the ticker INIFY.

Download press release - Inify Laboratories

Press Release Footer

About Euronext 
Euronext is the leading European capital market infrastructure, covering the entire capital markets value chain, from listing, trading, clearing, settlement and custody, to solutions for issuers and investors. Euronext runs MTS, one of Europe’s leading electronic fixed income trading markets, and Nord Pool, the European power market. Euronext also provides clearing and settlement services through Euronext Clearing and its Euronext Securities CSDs in Denmark, Italy, Norway, and Portugal. As of December 2024, Euronext’s regulated exchanges in Belgium, France, Ireland, Italy, the Netherlands, Norway, and Portugal host over 1,800 listed issuers with around €6 trillion in market capitalisation, a strong blue-chip franchise and the largest global centre for debt and fund listings. With a diverse domestic and international client base, Euronext handles 25% of European lit equity trading. Its products include equities, FX, ETFs, bonds, derivatives, commodities and indices. 
For the latest news, follow us on X (x.com/euronext) and LinkedIn (linkedin.com/company/euronext).

Disclaimer
This press release is for information purposes only and is not a recommendation to engage in investment activities. This press release is provided “as is” without representation or warranty of any kind. While all reasonable care has been taken to ensure the accuracy of the content, Euronext does not guarantee its accuracy or completeness. Euronext will not be held liable for any loss or damages of any nature ensuing from using, trusting or acting on information provided. No information set out or referred to in this publication may be regarded as creating any right or obligation. The creation of rights and obligations in respect of financial products that are traded on the exchanges operated by Euronext’s subsidiaries shall depend solely on the applicable rules of the market operator. All proprietary rights and interest in or connected with this publication shall vest in Euronext.

This press release speaks only as of this date. Euronext refers to Euronext N.V. and its affiliates. Information regarding trademarks and intellectual property rights of Euronext is located at www.euronext.com/terms-use.

© 2025, Euronext N.V. - All rights reserved.